MORC2, a Novel Oncogene, is Upregulated in Liver Cancer and Contributes to Proliferation, Metastasis and Chemoresistance

Overview

Journal Int J Oncol

Specialty Oncology

Date 2018 Apr 6

PMID 29620211

Citations 23

Authors

Zhihong Pan

Qianshan Ding

Qian Guo

Yong Guo

Lianlian Wu

Lu Wu

Meng Tang

Honggang Yu

Fuxiang Zhou

Affiliations

Soon will be listed here.

Abstract

Microrchidia 2 (MORC2) is important in DNA damage repair and lipogenesis, however, the clinical and functional role of MORC2 in liver cancer remains to be fully elucidated. The aim the present study was to clarify the role of MORC2 in liver cancer. Expression profile analysis, immunohistochemical staining, reverse transcription-quantitative polymerase chain reaction analysis and western blot analysis were performed to evaluate the levels of MORC2 in liver cancer patient specimens and cell lines; subsequently the expression of MORC2 was suppressed or increased in liver cancer cells and the effects of MORC2 on the cancerous transformation of liver cancer cells were examined in vitro and in vivo. MORC2 was upregulated in liver cancer tissues, and the upregulation was associated with certain clinicopathologic features of patients with liver cancer. MORC2 knockdown caused marked inhibition of liver cancer cell proliferation and clonogenicity, whereas the overexpression of MORC2 substantially promoted liver cancer cell proliferation. In addition, the knockdown of MORC2 inhibited the migratory and invasive ability of liver cancer cells, whereas increased migration and invasion rates were observed in cells with ectopic expression of MORC2. In a model of nude mice, the overexpression of MORC2 promoted tumorigenicity and markedly enhanced pulmonary metastasis of liver cancer. Furthermore, MORC2 regulated apoptosis and its expression level had an effect on the sensitivity of liver cancer cells to doxorubicin, 5-fluorouracil and cisplatin. Mechanically, MORC2 modulated the mitochondrial apoptotic pathway, possibly in a p53-dependent manner, and its dysregulation also resulted in the abnormal activation of the Hippo pathway. For the first time, to the best of our knowledge, the present study confirmed that MORC2 was a novel oncogene in liver cancer. These results provide useful insight into the mechanism underlying the tumorigenesis and progression of liver cancer, and offers clues into potential novel liver cancer therapies.

Citing Articles

CRISPR/Cas9 system: a novel approach to overcome chemotherapy and radiotherapy resistance in cancer.

Noruzi S, Mohammadi R, Jamialahmadi K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39560750 DOI: 10.1007/s00210-024-03480-2.

Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven Cytostasis.

Pearson J, Huang K, Dela Pena L, Ducarouge B, Mehlen P, Bremner R Cancer Res Commun. 2024; 4(9):2374-2383.

PMID: 39172021 PMC: 11384508. DOI: 10.1158/2767-9764.CRC-24-0101.

Emerging roles of the chromatin remodeler MORC2 in cancer metabolism.

Mohapatra B, Pakala S Med Oncol. 2024; 41(9):221.

PMID: 39117768 DOI: 10.1007/s12032-024-02464-9.

Novel Insights into the Role of Chromatin Remodeler MORC2 in Cancer.

Chutani N, Ragula S, Syed K, Pakala S Biomolecules. 2023; 13(10).

PMID: 37892209 PMC: 10605154. DOI: 10.3390/biom13101527.

Identifying Suitable Reference Gene Candidates for Quantification of DNA Damage-Induced Cellular Responses in Human U2OS Cell Culture System.

Barta N, Ordog N, Pantazi V, Berzsenyi I, Borsos B, Majoros H Biomolecules. 2023; 13(10).

PMID: 37892205 PMC: 10605043. DOI: 10.3390/biom13101523.

References

Liao X, Zhang Y, Dong W, Shao Z, Li D . Chromatin remodeling protein MORC2 promotes breast cancer invasion and metastasis through a PRD domain-mediated interaction with CTNND1. Oncotarget. 2017; 8(58):97941-97954. PMC: 5716704. DOI: 10.18632/oncotarget.18556. View

Yang S, Chang C, Wei R, Shiue Y, Wang S, Yeh Y . Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int. 2014; 2014:153867. PMC: 4022277. DOI: 10.1155/2014/153867. View

Stuhldreier F, Kassel S, Schumacher L, Wesselborg S, Proksch P, Fritz G . Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells. Cancer Lett. 2015; 361(1):39-48. DOI: 10.1016/j.canlet.2015.02.030. View

Moissiard G, Cokus S, Cary J, Feng S, Billi A, Stroud H . MORC family ATPases required for heterochromatin condensation and gene silencing. Science. 2012; 336(6087):1448-51. PMC: 3376212. DOI: 10.1126/science.1221472. View

Jia H, Cong Q, Chua J, Liu H, Xia X, Zhang X . p57Kip2 is an unrecognized DNA damage response effector molecule that functions in tumor suppression and chemoresistance. Oncogene. 2014; 34(27):3568-81. DOI: 10.1038/onc.2014.287. View

Li D, Nair S, Kumar R . The MORC family: new epigenetic regulators of transcription and DNA damage response. Epigenetics. 2013; 8(7):685-93. PMC: 3781187. DOI: 10.4161/epi.24976. View

Wang C, Rajput S, Watabe K, Liao D, Cao D . Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed). 2009; 2(2):515-26. DOI: 10.2741/s82. View

Roessler S, Jia H, Budhu A, Forgues M, Ye Q, Lee J . A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 2010; 70(24):10202-12. PMC: 3064515. DOI: 10.1158/0008-5472.CAN-10-2607. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

10.

Chen L, Kuo W, Tsai M, Chen P, Hsiao C, Chuang E . Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. PLoS One. 2011; 6(11):e28222. PMC: 3226667. DOI: 10.1371/journal.pone.0028222. View

11.

Hong L, Cai Y, Jiang M, Zhou D, Chen L . The Hippo signaling pathway in liver regeneration and tumorigenesis. Acta Biochim Biophys Sin (Shanghai). 2014; 47(1):46-52. DOI: 10.1093/abbs/gmu106. View

12.

Liu A, Yao T, Wang W, Wong K, Lee N, Fan S . Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012; 2(2):e000825. PMC: 3308260. DOI: 10.1136/bmjopen-2012-000825. View

13.

Bae J, Kim S, Lee H . The Hippo signaling pathway provides novel anti-cancer drug targets. Oncotarget. 2016; 8(9):16084-16098. PMC: 5362547. DOI: 10.18632/oncotarget.14306. View

14.

Sanchez-Solana B, Li D, Kumar R . Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochim Biophys Acta. 2013; 1843(2):316-26. PMC: 3923981. DOI: 10.1016/j.bbamcr.2013.11.012. View

15.

Lassuthova P, Safka Brozkova D, Krutova M, Mazanec R, Zuchner S, Gonzalez M . Severe axonal Charcot-Marie-Tooth disease with proximal weakness caused by de novo mutation in the MORC2 gene. Brain. 2016; 139(Pt 4):e26. PMC: 6276929. DOI: 10.1093/brain/awv411. View

16.

Calvisi D, Wang C, Ho C, Ladu S, Lee S, Mattu S . Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2010; 140(3):1071-83. PMC: 3057329. DOI: 10.1053/j.gastro.2010.12.006. View

17.

Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N . A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013; 154(5):1047-1059. DOI: 10.1016/j.cell.2013.07.042. View

18.

Cui X, Choi H, Choi Y, Park S, Sung G, Lee Y . DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 2014; 357(1):307-315. DOI: 10.1016/j.canlet.2014.11.041. View

19.

Shao Y, Li Y, Zhang J, Liu D, Liu F, Zhao Y . Involvement of histone deacetylation in MORC2-mediated down-regulation of carbonic anhydrase IX. Nucleic Acids Res. 2010; 38(9):2813-24. PMC: 2875037. DOI: 10.1093/nar/gkq006. View

20.

Zheng T, Wang J, Jiang H, Liu L . Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Lett. 2011; 302(2):91-9. DOI: 10.1016/j.canlet.2010.12.008. View